Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Molecular Partners Ag ADR (NQ: MOLN )

6.600 +0.310 (+4.93%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,800
Open 6.530
Bid (Size) 2.620 (1)
Ask (Size) 10.38 (2)
Prev. Close 6.290
Today's Range 6.470 - 6.600
52wk Range 5.500 - 8.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire

Performance

YTD
+2.80%
+2.80%
1 Month
-2.94%
-2.94%
3 Month
+10.37%
+10.37%
6 Month
-5.17%
-5.17%
1 Year
-4.76%
-4.76%

More News

Read More
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners Publishes Invitation to Annual General Meeting 2023
From Molecular Partners
Via GlobeNewswire
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
From Molecular Partners
Via GlobeNewswire
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
From Molecular Partners
Via GlobeNewswire
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
From Molecular Partners
Via GlobeNewswire
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
From Molecular Partners
Via GlobeNewswire
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
From Molecular Partners
Via GlobeNewswire
Molecular Partners Announces Planned Departure of Chief Financial Officer
From Molecular Partners
Via GlobeNewswire
Molecular Partners AG (NASDAQ:MOLN) Long Term Investor Alert: Investigation of Potential Wrongdoing
Via SBWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NASDAQ:MOLN Investor Notice: Deadline Coming Up on September 12, 2022 in Lawsuit Against Molecular Partners AG
Via SBWire
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Molecular Partners AG (MOLN) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
FINAL INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Molecular Partners AG with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
MOLN DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Molecular Partners AG Investors With Losses to Secure Counsel Before Important September 12 Deadline in Securities Class Action - MOLN
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures COVID-19 Financial Legal
MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.